drugset / Trial / NCT07054736
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will be a multicenter, randomized, double-blinded, placebo-controlled clinical study. It is planned to enroll 120 adult patients with moderate-to-severe Atopic Dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical treatments are medically inadvisable.
Timeline
- Start
- 2025-08-31
- Primary completion
- 2025-10-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | XKH001 | Monoclonal antibody | 100 mg | Subcutaneous |
| Comparator | XKH001 | Monoclonal antibody | 300 mg | Subcutaneous |
| Comparator | XKH001 | Monoclonal antibody | 600 mg | Subcutaneous |